Mission Statement, Vision, & Core Values of Microbot Medical Inc. (MBOT)

Microbot Medical Inc.'s (MBOT) Mission, Vision, and Core Values are not just corporate boilerplate; they are the fundamental justification for the company's current financial reality.

You're looking at a pre-commercial business that, despite reporting $0.00 in revenue for the trailing 12 months ending June 30, 2025, successfully raised approximately $30 million in early 2025 to fund the LIBERTY® Endovascular Robotic Surgical System's launch.

Does a deeply-held commitment to patient accessibility and surgical innovation defintely justify a Q3 2025 Earnings Per Share (EPS) miss of -$0.07, or are these values the only thing keeping the valuation afloat?

Microbot Medical Inc. (MBOT) Overview

You are looking at Microbot Medical Inc. (MBOT) because its micro-robotic technology is genuinely disruptive, but you need to know if the financials support the hype. The direct takeaway is that while the company is still pre-revenue, its strong cash position and the recent U.S. commercial launch of its flagship product, the LIBERTY® Endovascular Robotic System, are the definitive near-term opportunities to watch.

Microbot Medical, founded in 2010, is a medical device company focused on creating micro-robotic platforms for complex, minimally invasive procedures. The company's core innovation lies in its two primary technology divisions: the Endovascular platform and the Endoluminal platform. Their mission is to improve patient outcomes and enhance surgical precision by navigating the body's vascular and luminal pathways with proprietary microbot technology.

The company's flagship product is the LIBERTY® Endovascular Robotic System, which is the world's first fully disposable robotic system for endovascular procedures. This is a game-changer because a disposable system reduces cross-contamination risk and eliminates the need for expensive sterilization processes. As of November 2025, Microbot Medical is still in a pre-commercial stage, meaning it has not yet generated revenues from operations from its core products, which is a crucial detail for any investor.

• Founded: 2010 (as Microbot Medical Ltd.).
• Headquarters: Hingham, Massachusetts.
• Key Product: LIBERTY® Endovascular Robotic System.
• Current Sales: Pre-revenue from core products.

Here's the quick math: the company is burning cash on research and development (R&D) to get these systems to market, so sales are not the metric to track right now.

Latest Financial Performance and Commercial Launch

The latest financial report for the third quarter (Q3) of 2025, which ended September 30, 2025, confirms the development-stage profile. Microbot Medical reported a net loss of $3.58 million for the quarter, an increase from the $3.22 million net loss a year ago. Basic and diluted loss per share from continuing operations was $0.07 for Q3 2025.

You can't talk about 'record-breaking revenue' yet, but you can talk about a record-breaking cash position that fuels the commercial push. The company's financial health is underpinned by its strong liquidity, which is essential for a pre-revenue medical device company. As of September 30, 2025, Microbot Medical had cash and cash equivalents, plus marketable securities, totaling approximately $80.2 million. This liquid resource base is what supports the commercialization of the LIBERTY® system and ongoing R&D, and management believes these funds are sufficient to operate for more than twelve months.

The big news in November 2025 is the commencement of the Limited Market Release of the LIBERTY® Endovascular Robotic System in the U.S., following its FDA 510(k) clearance. This is the first step toward realizing the consensus revenue estimate of $5.63 million for the full Fiscal Year 2025, though this remains an estimate and not guaranteed revenue. If onboarding takes 14+ days, initial sales risk will rise, but this launch is the clear action that defines their near-term opportunity.

Microbot Medical's Position in Surgical Robotics

Microbot Medical is positioned as a key, innovative player in the surgical robotics market, not by size, but by technological differentiation. The company is targeting a massive opportunity: the estimated 2.5 million annual peripheral endovascular procedures in the U.S. alone. This substantial total addressable market (TAM) makes the LIBERTY® system's FDA clearance a significant catalyst.

The company's success hinges on two key factors: the system's unique fully disposable design and its potential to enhance procedure efficiency while lowering costs. This focus on a single-use robotic micro-surgical system sets it apart from larger competitors like Intuitive Surgical or Medtronic, whose systems often require significant upfront capital expenditures and complex sterilization. Microbot Medical is defintely one to watch as they move from development to commercialization. To understand the granular details of how this cash position and market entry translate into shareholder value, you should find out more below to understand why Microbot Medical is successful: Breaking Down Microbot Medical Inc. (MBOT) Financial Health: Key Insights for Investors

Microbot Medical Inc. (MBOT) Mission Statement

Microbot Medical Inc. is a pre-commercial stage medical technology company, so its mission statement is less about current revenue and more about its disruptive vision for the future of care. The company's core mission is to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally by eliminating traditional barriers to access advanced robotic systems. This mission is the strategic compass that guides every dollar of their R&D spend and commercial planning.

For a company that has not yet generated significant commercial revenue, like Microbot Medical Inc., a clear mission is defintely critical. It helps align investor capital-which has been substantial, with total cash and marketable securities reaching approximately $32.7 million as of June 30, 2025-with long-term product development goals. This clarity is what allows them to transition from a pure R&D entity to a sales-driven organization, especially following the commencement of the Limited Market Release of their LIBERTY® Endovascular Robotic System in the U.S. in November 2025.

Core Component 1: Redefining Endovascular Robotics Through Innovation

The first core component of the mission is a commitment to technological innovation, specifically by developing the world's first single-use, fully disposable endovascular robotic system. This is a direct challenge to the high-cost, multi-use models that currently dominate the surgical robotics market. Microbot Medical Inc. is not just building a robot; they are building a new economic model for robotic surgery.

Here's the quick math on their focus: The company's Trailing Twelve Months (TTM) Operating Expenses, as of June 30, 2025, were $13.47 million, with a significant portion, $7.39 million, dedicated to Research & Development (R&D). That R&D focus is what creates the intellectual property (IP) moat, which currently includes 12 granted U.S. patents and 57 pending applications. This IP expansion recently grew their addressable market from 2.5 million to 6 million annual procedures.

• Develop the world's first single-use, disposable endovascular robot.
• Invest R&D capital to expand the IP portfolio and market reach.
• Challenge the high-cost, reusable surgical robotics status quo.

Core Component 2: Improving Quality of Care and Patient Safety

The second pillar is about measurable clinical benefit and safety for both the patient and the provider. The LIBERTY® system is explicitly designed for precision, efficiency, and safety. This is where the rubber meets the road-or, in this case, where the robot meets the vessel.

The successful completion of the ACCESS-PVI human clinical trial provides concrete evidence of this commitment. In those studies, the system demonstrated a 92% reduction in radiation exposure for the physician. That's a huge win for the operator, who typically absorbs significant radiation during long, complex endovascular procedures. Plus, the system achieved a 100% technical success rate in the clinical studies, which is the kind of hard number that drives adoption. The company's net loss for the nine months ended September 30, 2025, was $9.68 million, which, while a loss, represents the cost of this rigorous, safety-focused clinical development. You can read more about the stakeholders driving this focus at Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who's Buying and Why?

Core Component 3: Eliminating Barriers and Driving Accessibility

The final, and perhaps most disruptive, component is the drive for global accessibility. Traditional robotic systems require massive capital expenditure (CapEx) and dedicated cath lab space, which locks out smaller hospitals and outpatient centers. Microbot Medical Inc.'s single-use, disposable design aims to eliminate these traditional barriers.

The key value proposition here is simple: cost. The single-use platform is projected to offer 30-50% cost savings compared to reusable robotic systems. This lower cost structure is what allows the technology to scale beyond major metropolitan academic centers and into underserved hospitals and outpatient settings. This shift in the economic model is crucial for a company with a current market capitalization of $142 million (as of November 12, 2025) that is looking to carve out a significant share of the estimated $30 billion surgical robotics market. Lowering the financial hurdle for hospitals is the clearest path to improving quality of care for millions of patients who currently lack access to advanced robotic intervention.

Microbot Medical Inc. (MBOT) Vision Statement

You're looking at Microbot Medical Inc. (MBOT) right at the most critical inflection point in its history-the transition from a research-stage company to a commercial one. Their vision is clear: to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. This is a massive goal, especially for a company with trailing 12-month revenue of only $0.00 as of June 30, 2025. Still, the September 2025 FDA clearance of their core product changes the entire risk profile.

The first part of the vision is about redefining the technology. Microbot Medical's answer is the LIBERTY® Endovascular Robotic Surgical System, which is the world's first single-use, fully disposable robotic system for endovascular procedures. This disposable nature is the key differentiator, aiming to eliminate the traditional barriers to entry for advanced robotics, like the huge capital expenditure and complex sterilization processes of older, multi-use systems. The company is defintely trying to democratize robotic surgery.

• Eliminate high capital costs for hospitals.
• Simplify setup and turnaround time.
• Reduce infection risk with single-use components.

Here's the quick math: the U.S. market for peripheral endovascular procedures is about 2.5 million annual cases, and LIBERTY® is designed to address a significant portion of that. The company is now capitalizing on its strong intellectual property (IP) portfolio to protect this unique position.

The second pillar of their vision is directly tied to patient and provider outcomes. The LIBERTY® System is engineered for enhanced precision, efficiency, and provider safety in complex endovascular procedures. This focus is a core value, translating directly into better patient care by reducing the physical strain on the physician and potentially minimizing procedure time and complication rates.

For the physician, the remote operation capability is a game-changer for safety. It moves the clinician away from the radiation source, reducing their lifetime exposure. This is a crucial selling point in the interventional space. The system's precision, backed by the successful completion of the ACCESS-PVI human clinical trial, is what will drive adoption. If onboarding takes 14+ days, adoption risk rises, but a disposable system should help simplify that process.

The final component of the vision-reaching 'millions of patients and providers globally'-is now being executed through a focused 2025 commercial strategy. After securing FDA 510(k) clearance on September 8, 2025, Microbot Medical commenced a limited market release in the U.S. on November 5, 2025, targeting high-demand regions.

To fund this push, the company has been active in capital markets. They raised approximately $30 million in early 2025 and secured up to an additional $92.2 million in gross proceeds from the exercise of preferred investment options in September 2025. This capital is essential for building out the commercial infrastructure, which includes hiring a seasoned sales team and partnering with a U.S.-based logistics company in October 2025. You can read more about the foundation of this strategy in Microbot Medical Inc. (MBOT): History, Ownership, Mission, How It Works & Makes Money. What this estimate hides, of course, is the burn rate, which resulted in a net loss of $3.5 million for Q2 2025. They have the capital to execute the launch, but sales must follow quickly.

Microbot Medical Inc. (MBOT) Core Values

You're looking for the bedrock of Microbot Medical Inc.'s (MBOT) strategy, the principles that guide their capital allocation and product roadmap. The direct takeaway is that their values-Innovation, Patient-Centric Precision, and Commercial Readiness-are not just boilerplate text; they are actively funded and reflected in their 2025 operational milestones, especially as they move from a development-stage company to a commercial one.

This is a pre-revenue company still building its foundation, so its values are defintely tied to execution. Their financial picture, with a net loss of -$12.71 million for the trailing twelve months ended June 30, 2025, shows they are spending heavily to realize this vision. But they are funding this work, having raised approximately $30 million in early 2025.

Innovation is Microbot Medical Inc.'s lifeblood; it's the core mandate for their existence. The company's vision is to redefine endovascular robotics, and that starts with the technology itself. They don't just want to build a better mousetrap; they want to build the world's first single-use, fully disposable endovascular robotic system, which is the LIBERTY® Endovascular Robotic System.

This commitment is backed by tangible investment, not just rhetoric. Here's the quick math: their Research & Development (R&D) expenses were $7.39 million for the trailing twelve months ending June 30, 2025, a clear priority over other operational costs. Also, to ensure their technology stays ahead, they secured a non-dilutive grant in August 2025 from the Israel Innovation Authority (IIA) for NIS 2.15 Million (about $630,000) to enhance manufacturing capabilities. That's smart, non-dilutive funding directly supporting their technological edge.

• Fund R&D with $7.39 million (TTM Jun '25).
• Secure $630,000 in non-dilutive grant funding.
• Develop the world's first single-use robotic system.

The second core value is a focus on the patient and provider-specifically, improving the quality of care for millions globally. In the medical device space, this translates to precision, efficiency, and safety. The LIBERTY® System is explicitly designed for these three elements in endovascular procedures.

For a company in this stage, the most concrete demonstration of this value is rigorous regulatory engagement. The fact that the LIBERTY® System received FDA clearance and began its limited market release in the U.S. in November 2025 is the ultimate proof point. This regulatory process is a multi-million-dollar commitment to patient safety and efficacy. Missing the Q3 2025 analyst consensus for EPS by $0.01 (reporting -$0.07) is a minor blip when you consider the cost of achieving this critical safety and market milestone.

You can see how this commitment plays out in the market profile. For a deeper dive into who is betting on this value proposition, you should read Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who's Buying and Why?

A great product is just an idea without a plan to get it to market. This value is all about the near-term action plan. Microbot Medical Inc. has been maniacally focused on building the commercial infrastructure needed for a successful launch in 2025 and 2026.

They are not waiting for the broad launch anticipated in April 2026. They started their Limited Market Release in the fourth quarter of 2025. To support this, they expanded their commercial team in June 2025, bringing in a head of Sales Operations & Analytics to optimize the sales cycle and accelerate execution. Plus, in October 2025, they partnered with a U.S. based third-party logistics (3PL) company to handle inventory management and customer support, ensuring a smooth supply chain from day one. That's a clear, executable plan.